Lucitanib Clinical Development Overview
Lucitanib, is an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRα/β) and fibroblast growth factor receptors 1 through 3 (FGFR 1-3). The LIO-1 Phase 2 study, evaluating lucitanib and nivolumab in gynecologic cancers has completed enrollment.
Clovis has global rights for lucitanib excluding China.
Lucitanib Scientific Presentations
LIO-1: Initial Phase 2 Experience of Lucitanib + Nivolumab in Patients With Metastatic or Recurrent Cervical Cancer (NCT04042116; ENGOT-GYN3/AGO/LIO)
Oral Presentation 2022 SGO Annual Meeting
Phase 1b/2 SEASTAR Trial: Safety, Pharmacokinetics, and Preliminary Efficacy of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Rucaparib and Angiogenesis Inhibitor Lucitanib in Patients with Advanced Solid Tumors
Poster Presentation 2021 ASCO Virtual Annual Meeting
LIO-1: Lucitanib + Nivolumab in Patients with Advanced Solid Tumors–Updated Phase 1b Results and Initial Experience in Phase 2 Ovarian Cancer Cohort (NCT04042116; ENGOT-GYN3/AGO/LIO)
Poster Presentation 2021 ASCO Virtual Annual Meeting
